Zeyome-企业战略
合作同方药业
-Tongfang Pharmaceutical Group is a 100-billion-dollar state-owned enterprise with its R&D headquarters located in San Diego, USA. It has more than 10 companies and has formed a development layout for the entire industry chain of drug R&D, production and sales. Tongfang Pharmaceutical has cooperated with Tsinghua University School of Pharmacy, Qingdao Agricultural University School of Life Sciences, BGI and other schools and enterprises, and has obtained more than ten R&D patents.
-Zeyome and Tongfang Pharmaceutical leverage their technical advantages to jointly develop anti-aging NAD+ products. This product uses the most advanced biotechnology and formula, has been verified by rigorous clinical trials, and has significant effects and safety. Its unique formula can activate NAD+ levels in the human body, improve the energy and metabolic capabilities of cells, thereby delaying the aging process and improving physical health.
-Zeyome is committed to bringing the most cutting-edge health technology and products to consumers around the world and protecting people's health. The company will continue to adhere to the concept of "technology leads health", continue to launch more innovative health products and solutions, and make greater contributions to the development of human health.
关于同方药业集团
同方药业集团有限公司前身为紫光制药有限公司，位于北京市延庆区八达岭镇西康路23号（中关村科技园区延庆园），属于国家高新技术和中关村高新技术企业，注册资金20,000万元，是由山西建设投资集团有限公司控股的大健康产业板块的综合性医药企业，母公司为香港主板上市公司华控康泰集团有限公司（股票代码HK.01312）。
目前同方药业集团旗下拥有同方药业集团有限公司、华控创新（北京）药物研究院有限公司、重庆康乐制药有限公司、重庆华控康乐药物研究有限公司等多家控股子公司。
同方药业一直与清华大学药学院、化工系等院系保持战略合作，通过优化产学研一体化机制、明晰发展战略，积极整合优秀的医药资源，提升大健康产业的系统竞争力，逐步将同方药业打造成综合性的医药产业集团。